December 23, 2019 / 7:48 PM / a month ago

Allergan's acute migraine treatment wins U.S. FDA approval

Dec 23 (Reuters) - The U.S. Food and Drug Administration said on Monday it had approved Allergan Plc’s drug for treating acute migraine in adults.

The drug, Ubrelvy, is the first oral version of a new class of drugs called CGRP inhibitors to win the FDA's approval for treating the neurological disease. (bit.ly/2QeY1b7)

The new class of drugs acts by interfering with CGRP, a protein involved in causing severe headaches.

Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below